U.S. CDC Recommends Novavax COVID-19 Vaccine for Adults

The United States Centers for Disease Control and Prevention (CDC) recommended the Novavax COVID-19 vaccine as a two-dose primary series in adults.

CDC Director Rochelle Walensky endorsed the recommendation of the CDC Advisory Committee on Immunization Practices (ACIP) to use the Novavax vaccine for those aged 18 and older, making it the fourth COVID-19 vaccine available in the U.S.

Earlier in the day, ACIP voted unanimously to recommend the vaccine after the U.S. Food and Drug Administration authorized it for emergency use last week.

CDC called the Novavax vaccine “an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adults.”

The Novavax vaccine uses a traditional protein-based approach, unlike the previous COVID-19 vaccines, such as the ones developed by Pfizer-BioNTech and Moderna, which used mRNA technology.

“Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers,” the CDC said.

The final recommendation has paved the way for 3.2 million doses of the Novavax vaccine to get shipped to the U.S.

In a statement, Biden called the recommendation “another step forward in our nation’s fight against the virus.”

“The science and data are clear: vaccines continue to protect people from serious illness, hospitalizations, and death — and with BA.5 increasing infections, it is essential that people get themselves and their kids vaccinated and stay up to date on their COVID-19 vaccinations,” Biden said.

According to the CDC, 78.5% of the U.S. population has received at least one dose of a COVID-19 vaccine.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.